CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
rSh28GSTbiological
Likely dose
rSh28GST 100µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01512277
NCT01512277Phase 1Completed
CompareCT.gov

Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis

University Hospital, Lille·interventional·Posted Jan 19, 2012·Updated Aug 27, 2013

In Brief

A Phase 1 clinical trial evaluating rSh28GST for Schistosomiasis and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this clinical study is to evaluate safety and immunogenicity in adult healthy volunteers of the vaccine candidate against schistosomiasis named Bilhvax.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchistosomiasis, Bilharziasis, Urinary Schistosomiasis
CountriesFrance
CollaboratorsInstitut National de la Santé Et de la Recherche Médicale, France

Timeline

Phase 1CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 19, 2012
Enrollment StartSep 1, 1998
Primary CompletionMar 1, 1999
Study CompletionSep 1, 1999
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.5 years ago

Interventions

rSh28GSTbiological

subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1